Quarterly Report Q1 2016

April 16, 2018

Prometic reports its first quarter 2016 highlights and financial results

 

  •  PBI-4050’s positive effects on novel biomarkers confirmed in metabolic syndrome and type 2 diabetes patients
  •  Strengthened balance sheet with $30 million follow-on debt financing from Structured Alpha LP, and $60 million bought deal equity financing
  • 2016 first quarter revenues of $5.2 million vs. $1.9 million for the 2015 first quarter
Previous Flipbook
Quarterly Report Q2 2016
Quarterly Report Q2 2016

Prometic reports second quarter 2016 highlights and financial results

No More Flipbooks